|
|
A New York woman has filed a lawsuit against the manufacturer of the irritable bowel syndrome medication Zelnorm, alleging that she suffered a stroke as a result of the drug’s side effects. Laurie Litwiniak’s lawsuit alleges that Novartis Pharmaceuticals downplayed the risks of taking Zelnorm after reports about the dangers of the drug began to emerge in 2007.
Read more...
A study examining the marketing of prescription drugs found that the manufacturer of the irritable bowel syndrome drug Zelnorm spent $249 million on advertising in its first year on the market. The study by researchers at the University of North Carolina-Chapel Hill found that the advertisements resulted in one million new doctors appointments over the first three months after the ads began running.
Read more...
An Iowa woman has filed a lawsuit against the manufacturer of the irritable bowel syndrome drug Zelnorm, alleging that the drug caused her to suffer permanent heart problems. The Food and Drug Administration ordered Novartis Pharmaceuticals to recall Zelnorm in 2007 after studies showed it caused an increased risk of cardiovascular side effects.
Read more...
The manufacturer of Zelnorm has announced that it will only make the drug available to patients in emergency situations with the approval of the Food and Drug Administration. Novartis Pharmaceuticals agreed to stop marketing Zelnorm in March 2007 after it was linked to an increased risk of heart attack, stroke and chest pain. The company was later allowed by the FDA to provide the drug to a limited number of patients.
Read more...
The Food and Drug Administration and the manufacturer of Zelnorm have placed further restrictions on the types of patients who can be treated with the irritable bowel syndrome (IBS) medication. The new restrictions come more than one year after Zelnorm was recalled in the U.S. after evidence suggested it could cause an increased risk of heart attack or stroke.
Read more...
|
|
